Brought to you by 
Forty Seven enters trial collaborations with Merck KGAA and Genentech
12 Jul 2019
Executive Summary
Forty Seven Inc. entered into trial collaborations with Merck KGAA and Genentech Inc. to evaluate its own antibody Hu5F9G4 as a potential combination therapy for ovarian and bladder cancers and leukemia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com